SLR Investment Corp. (SLRC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. SLR Investment Corp. is an externally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company invests primarily in leveraged middle-market companies through senior secured loans, financing leases, and equity securities. As of June 30, 2024, the portfolio consisted of 138 portfolio companies.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Net Investment Income | $24.3 million | $48.2 million | $44.8 million |
| Net Increase in Net Assets from Operations | $23.2 million | $51.1 million | $25.8 million |
| Earnings Per Share (Basic & Diluted) | $0.43 | $0.94 | $0.47 |
| Net Asset Value (NAV) Per Share | $18.20 | $18.20 | $17.98 |
| Total Debt Outstanding (Face Amount) | $1.159 billion | $1.159 billion | $1.183 billion |
| Cash and Cash Equivalents | $285.2 million | $285.2 million | $347.6 million |
| Portfolio Turnover Ratio | N/A | 9.0% | 12.6% |
Material Changes vs. Prior Period
- Revenue Growth: Gross investment income increased to $59.0 million for Q2 2024 from $56.3 million in Q2 2023, driven by portfolio growth (specifically the SLR Senior Lending Program) and higher index rates.
- Expense Increase: Net expenses rose to $34.7 million in Q2 2024 from $33.7 million in Q2 2023. This was primarily due to higher incentive fees on increased net investment income and higher interest expenses on a larger average credit facility balance.
- Unrealized Gains/Losses: The Company reported a net unrealized loss of $1.2 million for Q2 2024, compared to a loss of $4.2 million in Q2 2023. The Q2 2024 loss was driven by depreciation in SLR Equipment Finance and NSPC Intermediate Corp., partially offset by appreciation in Neuronetics, Inc. and SLR Credit Solutions.
- Debt Reduction: Total debt face amount decreased slightly from $1.183 billion at year-end 2023 to $1.159 billion at June 30, 2024.
Guidance, Outlook, and Risks
- Distributions: On August 7, 2024, the Board declared a quarterly distribution of $0.41 per share, payable September 27, 2024, to holders of record as of September 13, 2024.
- Stock Repurchase Program: The Board authorized an extension of a program to repurchase up to $50 million of common stock, effective until May 7, 2025. No shares were repurchased in the first half of 2024.
- Market Risk: The Company is exposed to interest rate risk. A hypothetical 1% increase in SOFR would increase net investment income by approximately $0.07 per share annually, while a 1% decrease would reduce it by the same amount. As of June 30, 2024, the Company held no interest rate hedging instruments.
- Contingencies: The Company had unfunded commitments of $183.8 million as of June 30, 2024, down from $248.7 million at year-end 2023. Management is not aware of any material pending litigation.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with asset coverage ratios and minimum stockholder equity requirements under the Credit Facility and SPV Credit Facility.
- Portfolio Concentration: Review the top 10 portfolio companies by fair value to assess concentration risk, particularly in the healthcare and financial services sectors.
- Non-Accrual Status: Confirm the status of the single issuer on non-accrual status as of June 30, 2024, and any potential impact on future income recognition.
- PIK Income: Assess the level of Payment-in-Kind (PIK) income capitalized ($4.9 million YTD 2024) versus cash collections to evaluate liquidity sustainability.
- Unfunded Commitments: Monitor the drawdown of the $183.8 million in unfunded commitments and the Company's ability to fund them without additional capital raises.